Update on IAS-Durban: Focus on ART
Roy M. Gulick, MD, MPH
Rochelle Belfer Professor in Medicine
Chief, Division of Infectious Diseases
Weill Cornell Medicine, New York, NY
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2016. All rights reserved.
Dr. Gulick is Rochelle Belfer Professor in Medicine and Chief of the Division of Infectious Diseases at Weill Cornell Medicine, and Attending Physician at the New York Presbyterian Hospital in New York City. He is board certified in internal medicine and infectious diseases. Dr. Gulick’s research interests include designing, conducting and analyzing clinical trials to refine antiretroviral therapy strategies for HIV treatment and prevention and assess antiretroviral agents with new mechanisms of action. He currently serves as Principal Investigator of the Cornell-New Jersey HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG) and the HIV Prevention Trials Network (HPTN), sponsored by the U.S. National Institutes of Health. He also serves as the Co-Chair of the U.S. Department of Health and Human Services (DHHS) Panel on Clinical Practices for Treatment of HIV Infection, Chair of the NIH Office of AIDS Research Advisory Committee (OARAC), a Board Member of the International Antiviral Society-USA, and previously served as a Member and as Chairman of the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA). He is a Member of the American Society of Clinical Investigation, the Association of American Physicians, International AIDS Society, and the Infectious Diseases Society of America, and has presented at national and international meetings and published widely.
At the completion of this educational session, learners will:
- Appreciate the latest epidemiologic data on HIV/AIDS.
- Be aware of the latest data from the International AIDS Society Durban meeting on treatment of HIV disease.
- Learn about the latest data from the International AIDS Society Durban meeting on prevention of HIV infection.
This PRN CME activity is funded in part by unrestricted educational grants from:
Bristol-Myers Squibb, Gilead Sciences, Merck & Co, and ViiV Healthcare.
